Lucid Diagnostics raises $13.625M via sale of Series A Convertible Preferred Stock

Lucid Diagnostics Inc.

Sold 13,625 shares of Series A Convertible Preferred at $1,000/share for gross proceeds of $13.625M.
Each share convertible into common stock at initial conversion price of $1.394 per share.
Preferred stock ranks senior to common stock; holders have no voting rights except as required by law.
Company executed a Registration Rights Agreement for resale of common shares issuable on conversion.
Offering exempt from registration under Section 4(a)(2) of Securities Act; purchasers are accredited investors.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Lucid Diagnostics Inc.: Amended and restated certificate of incorporation authorizing 20,000,000 shares of preferred stock and designating up to 20,000 shares as Series A Preferred Stock.

Change: charter amendment

Exact text from the filing

The Amended and Restated Certificate of Incorporation of the Company authorizes the issuance of up to 20,000,000 shares of preferred stock, par value $0.001 per share, and further authorizes the Board of the Company to fix and determine the designation, preferences, conversion rights, or other rights, including voting rights, qualifications, limitations, or restrictions of the preferred stock. The Certificate of Designation designates up to 20,000 of the shares of preferred stock as Series A Preferred Stock.

View on SEC.gov

Browse all governance changes →

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-007447

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.